sábado, 7 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 7, 2026

Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking?

View original at finance.yahoo.com
Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking? U.S. dealmaking activity was muted in early 2025 as macroeconomic uncertainty and tariff-related concerns weighed on corporate and private equity decision-making…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Asset Management unit intends to expand private credit portfolio to $300 billion by 2029

    80% confidence

  • Nearly 69% of respondents describe the M&A environment as strong, and 90% expect deal activity to increase or remain steady

    80% confidence

  • OneGS 3.0 is a multi-year overhaul that embeds AI as a core operating capability rather than a standalone tool

    80% confidence

  • Company targets mid-term goals of 14-16% return on equity and 60% efficiency ratio

    80% confidence

  • Zacks Consensus Estimate for Goldman's 2025 and 2026 earnings implies year-over-year growth of 20.8% and 12.8% respectively

    80% confidence

  • Goldman Sachs carries Zacks Rank #2 (Buy) rating

    80% confidence

  • Goldman topped global M&A rankings in 2025 by hitting $1.66 trillion in volume, advising on 40 megadeals and achieving market share of 36.4%

    80% confidence

  • Only 48% of private equity leaders felt confident pursuing M&A in Q1 2025, but confidence surged to 86% by year-end

    80% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com
Should You Buy Goldman Stock as Macro Clarity Rekindles Dealmaking? — Source | Via News | es.VIA.NEWS